🔬 Expanding our integrated capabilities in autoimmune research
September 3, 2025

At Pharmidex, we are proud to offer a comprehensive preclinical platform for autoimmune disease research.


Using in vivo EAE models, we combine:

 ✔️ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression

 ✔️ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs

 ✔️ Pharmacological intervention studies, including established treatments


This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation.


By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects.


👉 Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.

Expanding our integrated capabilities in autoimmune research

Pharmidex has joined the Good Clinical Practice (GCP) Network

February 17, 2026
We’re proud to announce that Pharmidex has joined the Good Clinical Practice (GCP) Network , a global collaboration advancing ICH-GCP excellence in clinical research. For us, quality and data integrity are not box-ticking exercises, they are fundamental to credible science and responsible drug development. From pre-clinical research through to clinical delivery, we are committed to: • Regulatory rigour • Ethical conduct • Participant protection • Scientifically robust data Joining the GCP Network further strengthens that commitment. We look forward to contributing to a global community dedicated to raising the bar across clinical research.

🔬 New at Pharmidex: In Vivo CAR-T Studies

February 12, 2026
Pharmidex now offers integrated in vivo CAR-T study support , combining robust in-life pharmacology with advanced f low cytometry –based cellular analysis. We support early-stage CAR-T and cell therapy programmes with translational data on efficacy, expansion, persistence and phenotype delivered through a single collaborative CRO partner. Let’s talk. 🌐 www.pharmidex.com

📍 Innovate Cambridge x Founders Growth Community | 12 Feb 2026

February 11, 2026
Pharmidex is pleased to share that Janette Dalay Robertson will be attending the Founders Growth Community Meeting and Networking x Innovate Cambridge event at The Glasshouse, Cambridge. Janette will be available to meet between 12:00–15:30 and looks forward to connecting with fellow attendees to explore new alliances in pre-clinical and clinical drug development. If you’re attending, let’s connect.
More Posts